Germ-Line BRCA1 Mutations in Jewish and Non-Jewish Women with Early-Onset Breast Cancer
Michael G. FitzGerald, B.A., Deborah J. MacDonald, R.N., M.S., Michael Krainer, M.D., Ingrid Hoover, B.A., Erin O'Neil, B.A., Hilal Unsal, M.D., Sandra Silva-Arrieto, B.A., Dianne M. Finkelstein, Ph.D., Peggy Beer-Romero, M.S., Christoph Englert, Ph.D., Dennis C. Sgroi, M.D., Barbara L. Smith, M.D., Ph.D., Jerry W. Younger, M.D., Judy E. Garber, M.D., Rosemary B. Duda, M.D., Kathleen A. Mayzel, M.D., Kurt J. Isselbacher, M.D., Stephen H. Friend, M.D., Ph.D., and Daniel A. Haber, M.D., Ph.D.
Background Mutations in a germ-line allele of the BRCA1 genecontribute to the familial breast cancer syndrome. However,the prevalence of these mutations is unknown in women with breastcancer who do not have the features of this familial syndrome.We sought BRCA1 mutations in women who were given a diagnosisof breast cancer at an early age, because early onset is characteristicof a genetic predisposition to cancer.
Methods Clinical information and peripheral-blood mononuclearcells were obtained from 418 women from the Boston metropolitanarea in whom breast cancer was diagnosed at or before the ageof 40. A comprehensive BRCA1 mutational analysis, involvingautomated nucleotide sequencing and a protein-truncation assay,was undertaken in 30 of these women, who had breast cancer beforethe age of 30. In addition, the BRCA1 mutation 185delAG, whichis prevalent in the Ashkenazi Jewish population, was soughtwith an allele-specific polymerase-chain-reaction assay in 39Jewish women among the 418 women who had breast cancer at orbefore the age of 40.
Results Among 30 women with breast cancer before the age of30, 4 (13 percent) had definite, chain-terminating mutationsand 1 had a missense mutation. Two of the four Jewish womenin this cohort had the 185delAG mutation. Among the 39 Jewishwomen with breast cancer at or before the age of 40, 8 (21 percent)carried the 185delAG mutation (95 percent confidence interval,9 to 36 percent).
Conclusions Germ-line BRCA1 mutations can be present in youngwomen with breast cancer who do not belong to families withmultiple affected members. The specific BRCA1 mutation knownas 185delAG is strongly associated with the onset of breastcancer in Jewish women before the age of 40.
Source Information
From the Center for Cancer Risk Analysis and the Massachusetts General Hospital Cancer Center, Charlestown, Mass. (M.G.F., D.J.M., M.K., I.H., E.O., H.U., S.S.-A., P.B.-R., C.E., K.J.I., S.H.F., D.A.H.); and the Departments of Pathology (D.C.S.) and Medical and Surgical Oncology (D.M.F., B.L.S., J.W.Y., D.A.H.), Massachusetts General Hospital; the Department of Biostatistics, Harvard School of Public Health (D.M.F.); Dana–Farber Cancer Institute (J.E.G.); Beth Israel Hospital (R.B.D.); and Faulkner Hospital (K.A.M.) — all in Boston.
Address reprint requests to Dr. Haber at MGH Cancer Center, CNY7, Bldg. 149, Charlestown, MA 02129.
Breast Cancer and BRCA1 Mutations
Offit K., Mathew C. G., Solomon E., Hodgson S. V., Ithier G., Girard M., Stoppa-Lyonnet D., Sher C., Sharabani-Gargir L., Shohat M., Haber D. A., Garber J. E., Finkelstein D. M., Langston A. A., Malone K. E., Ostrander E. A.
Extract |
Full Text
N Engl J Med 1996;
334:1197-1200, May 2, 1996.
Correspondence
This article has been cited by other articles:
Kim, J. K., Kwak, B. S., Lee, J. S., Hong, S. J., Kim, H. J., Son, B. H., Ahn, S. H.
(2007). Do Very Young Korean Breast Cancer Patients Have Worse Outcomes?. Ann. Surg. Oncol.
14: 3385-3391
[Abstract][Full Text]
Buckley, N. E., Hosey, A. M., Gorski, J. J., Purcell, J. W., Mulligan, J. M., Harkin, D. P., Mullan, P. B.
(2007). BRCA1 Regulates IFN-{gamma} Signaling through a Mechanism Involving the Type I IFNs. Mol Cancer Res
5: 261-270
[Abstract][Full Text]
Claus, E. B., Petruzella, S., Matloff, E., Carter, D.
(2005). Prevalence of BRCA1 and BRCA2 Mutations in Women Diagnosed With Ductal Carcinoma In Situ. JAMA
293: 964-969
[Abstract][Full Text]
Gilmore, P. M., McCabe, N., Quinn, J. E., Kennedy, R. D., Gorski, J. J., Andrews, H. N., McWilliams, S., Carty, M., Mullan, P. B., Duprex, W. P., Liu, E. T., Johnston, P. G., Harkin, D. P.
(2004). BRCA1 Interacts with and Is Required for Paclitaxel-Induced Activation of Mitogen-Activated Protein Kinase Kinase Kinase 3. Cancer Res.
64: 4148-4154
[Abstract][Full Text]
Thull, D. L., Vogel, V. G.
(2004). Recognition and Management of Hereditary Breast Cancer Syndromes. The Oncologist
9: 13-24
[Abstract][Full Text]
Domchek, S. M., Eisen, A., Calzone, K., Stopfer, J., Blackwood, A., Weber, B. L.
(2003). Application of Breast Cancer Risk Prediction Models in Clinical Practice. JCO
21: 593-601
[Abstract][Full Text]
Otis, C. N., Krebs, P. A., Albuquerque, A., Quezado, M. M., Juan, X. S., Sobel, M. E., Merino, M. J.
(2002). Loss of Heterozygosity of p53, BRCA1, VHL, and Estrogen Receptor Genes in Breast Carcinoma: Correlation with Related Protein Products and Morphologic Features. INT J SURG PATHOL
10: 237-245
[Abstract]
Andrews, H. N., Mullan, P. B., McWilliams, S., Sebelova, S., Quinn, J. E., Gilmore, P. M., McCabe, N., Pace, A., Koller, B., Johnston, P. G., Haber, D. A., Harkin, D. P.
(2002). BRCA1 Regulates the Interferon gamma -mediated Apoptotic Response. J. Biol. Chem.
277: 26225-26232
[Abstract][Full Text]
MacDonald, D J, Choi, J, Ferrell, B, Sand, S, McCaffrey, S, Blazer, K R, Grant, M, Weitzel, J N
(2002). Concerns of women presenting to a comprehensive cancer centre for genetic cancer risk assessment. J. Med. Genet.
39: 526-530
[Full Text]
Berry, D. A., Iversen, E. S. Jr, Gudbjartsson, D. F., Hiller, E. H., Garber, J. E., Peshkin, B. N., Lerman, C., Watson, P., Lynch, H. T., Hilsenbeck, S. G., Rubinstein, W. S., Hughes, K. S., Parmigiani, G.
(2002). BRCAPRO Validation, Sensitivity of Genetic Testing of BRCA1/BRCA2, and Prevalence of Other Breast Cancer Susceptibility Genes. JCO
20: 2701-2712
[Abstract][Full Text]
Loman, N., Johannsson, O., Kristoffersson, U., Olsson, H., Borg, A.
(2001). Family History of Breast and Ovarian Cancers and BRCA1 and BRCA2 Mutations in a Population-Based Series of Early-Onset Breast Cancer. JNCI J Natl Cancer Inst
93: 1215-1223
[Abstract][Full Text]
Harkin, D. P.
(2000). Uncovering Functionally Relevant Signaling Pathways Using Microarray-Based Expression Profiling. The Oncologist
5: 501-507
[Abstract][Full Text]
Chaudhuri, S., Cariappa, A., Tang, M., Bell, D., Haber, D. A., Isselbacher, K. J., Finkelstein, D., Forcione, D., Pillai, S.
(2000). Genetic susceptibility to breast cancer: HLA DQB*03032 and HLA DRB1*11 may represent protective alleles. Proc. Natl. Acad. Sci. USA
97: 11451-11454
[Abstract][Full Text]
ELLIS, D., GREENMAN, J., HODGSON, S., McCALL, S., LALLOO, F., CAMERON, J., IZATT, L., SCOTT, G., JACOBS, C., WATTS, S., CHORLEY, W., PERRETT, C., MACDERMOT, K., MOHAMMED, S., EVANS, G., MATHEW, C. G
(2000). Low prevalence of germline BRCA1 mutations in early onset breast cancer without a family history. J. Med. Genet.
37: 792-794
[Full Text]
Tsao, H., Zhang, X., Kwitkiwski, K., Finkelstein, D. M., Sober, A. J., Haluska, F. G.
(2000). Low Prevalence of Germline CDKN2A and CDK4 Mutations in Patients With Early-Onset Melanoma. Arch Dermatol
136: 1118-1122
[Abstract][Full Text]
Martin, A.-M., Weber, B. L.
(2000). Genetic and Hormonal Risk Factors in Breast Cancer. JNCI J Natl Cancer Inst
92: 1126-1135
[Abstract][Full Text]
LAVIE, O., HORNREICH, G., BEN ARIE, A., RENBAUM, P., LEVY-LAHAD, E., BELLER, U.
(2000). BRCA1 Germline Mutations in Women With Uterine Serous Papillary Carcinoma. Obstet Gynecol
96: 28-32
[Abstract][Full Text]
Penson, R. T., Seiden, M. V., Shannon, K. M., Lubratovich, M. L., Roche, M., Chabner, B. A., Lynch, T. J. Jr.
(2000). Communicating Genetic Risk: Pros, Cons, and Counsel. The Oncologist
5: 152-161
[Abstract][Full Text]
Eccles, D M, Evans, D G R, Mackay, J
(2000). Guidelines for a genetic risk based approach to advising women with a family history of breast cancer. J. Med. Genet.
37: 203-209
[Abstract][Full Text]
Haber, D. A.
(1999). Breast Cancer in Carriers of BRCA1 and BRCA2 Mutations: Tackling a Molecular and Clinical Conundrum. JCO
17: 3367-3370
[Full Text]
Phillips, K.-A., Andrulis, I. L., Goodwin, P. J.
(1999). Breast Carcinomas Arising in Carriers of Mutations in BRCA1 or BRCA2: Are They Prognostically Different?. JCO
17: 3653-3663
[Abstract][Full Text]
Turner, B. C., Harrold, E., Matloff, E., Smith, T., Gumbs, A. A., Beinfield, M., Ward, B., Skolnick, M., Glazer, P. M., Thomas, A., Haffty, B. G.
(1999). BRCA1/BRCA2 Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With BRCA1/BRCA2 Mutations. JCO
17: 3017-3024
[Abstract][Full Text]
Bell, D. W., Wahrer, D. C. R., Kang, D. H., MacMahon, M. S., FitzGerald, M. G., Ishioka, C., Isselbacher, K. J., Krainer, M., Haber, D. A.
(1999). Common Nonsense Mutations in RAD52. Cancer Res.
59: 3883-3888
[Abstract][Full Text]
Chan, P. C. R., Wong, B. Y.L., Ozcelik, H., Cole, D. E.C.
(1999). Simple and Rapid Detection of BRCA1 and BRCA2 Mutations by Multiplex Mutagenically Separated PCR. Clin. Chem.
45: 1285-1287
[Full Text]
Warner, E., Foulkes, W., Goodwin, P., Meschino, W., Blondal, J., Paterson, C., Ozcelik, H., Goss, P., Allingham-Hawkins, D., Hamel, N., Di Prospero, L., Contiga, V., Serruya, C., Klein, M., Moslehi, R., Honeyford, J., Liede, A., Glendon, G., Brunet, J.-S., Narod, S.
(1999). Prevalence and Penetrance of BRCA1 and BRCA2 Gene Mutations in Unselected Ashkenazi Jewish Women With Breast Cancer. JNCI J Natl Cancer Inst
91: 1241-1247
[Abstract][Full Text]
Tong, D., Stimpfl, M., Reinthaller, A., Vavra, N., Mullauer-Ertl, S., Leodolter, S., Zeillinger, R.
(1999). BRCA1 Gene Mutations in Sporadic Ovarian Carcinomas: Detection by PCR and Reverse Allele-specific Oligonucleotide Hybridization. Clin. Chem.
45: 976-981
[Abstract][Full Text]
Peto, J., Collins, N., Barfoot, R., Seal, S., Warren, W., Rahman, N., Easton, D. F., Evans, C., Deacon, J., Stratton, M. R.
(1999). Prevalence of BRCA1 and BRCA2 Gene Mutations in Patients With Early-Onset Breast Cancer. JNCI J Natl Cancer Inst
91: 943-949
[Abstract][Full Text]
Hodgson, S. V, Heap, E., Cameron, J., Ellis, D., Mathew, C. G, Eeles, R. A, Solomon, E., Lewis, C. M
(1999). Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer. J. Med. Genet.
36: 369-373
[Abstract][Full Text]
Frank, T. S.
(1998). Hereditary Risk of Breast and Ovarian Carcinoma: The Role of the Oncologist. The Oncologist
3: 403-412
[Abstract][Full Text]
Fentiman, I. S
(1998). Prophylactic mastectomy: deliverance or delusion?. BMJ
317: 1402-1403
[Full Text]
Lopez-Otin, C., Diamandis, E. P.
(1998). Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical Features. Endocr. Rev.
19: 365-396
[Abstract][Full Text]
Newman, B., Mu, H., Butler, L. M., Millikan, R. C., Moorman, P. G., King, M.-C.
(1998). Frequency of Breast Cancer Attributable to BRCA1 in a Population-Based Series of American Women. JAMA
279: 915-921
[Abstract][Full Text]
Malone, K. E., Daling, J. R., Thompson, J. D., O'Brien, C. A., Francisco, L. V., Ostrander, E. A.
(1998). BRCA1 Mutations and Breast Cancer in the General Population: Analyses in Women Before Age 35 Years and in Women Before Age 45 Years With First-Degree Family History. JAMA
279: 922-929
[Abstract][Full Text]
Couch, F. J., Hartmann, L. C.
(1998). BRCA1 Testing--Advances and Retreats. JAMA
279: 955-957
[Full Text]
Perera, F. P.
(1997). Environment and Cancer: Who Are Susceptible?. Science
278: 1068-1073
[Abstract][Full Text]
Grogan, L., Kirsch, I.R.
(1997). Genetic Testing for Cancer Risk Assessment: A Review. The Oncologist
2: 208-222
[Abstract][Full Text]
Ruffner, H., Verma, I. M.
(1997). BRCA1 is a cell cycle-regulated nuclear phosphoprotein. Proc. Natl. Acad. Sci. USA
94: 7138-7143
[Abstract][Full Text]
Side, L., Taylor, B., Cayouette, M., Conner, E., Thompson, P., Luce, M., Shannon, K.
(1997). Homozygous Inactivation of the NF1 Gene in Bone Marrow Cells from Children with Neurofibromatosis Type 1 and Malignant Myeloid Disorders. NEJM
336: 1713-1720
[Abstract][Full Text]
Struewing, J. P., Hartge, P., Wacholder, S., Baker, S. M., Berlin, M., McAdams, M., Timmerman, M. M., Brody, L. C., Tucker, M. A.
(1997). The Risk of Cancer Associated with Specific Mutations of BRCA1 and BRCA2 among Ashkenazi Jews. NEJM
336: 1401-1408
[Abstract][Full Text]
Couch, F. J., DeShano, M. L., Blackwood, M. A., Calzone, K., Stopfer, J., Campeau, L., Ganguly, A., Rebbeck, T., Weber, B. L., Jablon, L., Cobleigh, M. A., Hoskins, K., Garber, J. E.
(1997). BRCA1 Mutations in Women Attending Clinics That Evaluate the Risk of Breast Cancer. NEJM
336: 1409-1415
[Abstract][Full Text]
Krainer, M., Silva-Arrieta, S., FitzGerald, M. G., Shimada, A., Ishioka, C., Kanamaru, R., MacDonald, D. J., Unsal, H., Finkelstein, D. M., Bowcock, A., Isselbacher, K. J., Haber, D. A.
(1997). Differential Contributions of BRCA1 and BRCA2 to Early-Onset Breast Cancer. NEJM
336: 1416-1422
[Abstract][Full Text]
Sellers, T. A.
(1997). Genetic Factors in the Pathogenesis of Breast Cancer: Their Role and Relative Importance. J. Nutr.
127
: 929S-929S
[Abstract][Full Text]
Stratton, J. F., Gayther, S. A., Russell, P., Dearden, J., Gore, M., Blake, P., Easton, D., Ponder, B. A.J.
(1997). Contribution of BRCA1 Mutations to Ovarian Cancer. NEJM
336: 1125-1130
[Abstract][Full Text]
Ishioka, C., Suzuki, T., FitzGerald, M., Krainer, M., Shimodaira, H., Shimada, A., Nomizu, T., Isselbacher, K. J., Haber, D., Kanamaru, R.
(1997). Detection of heterozygous truncating mutations in the BRCA1 and APC genes by using a rapid screening assay in yeast. Proc. Natl. Acad. Sci. USA
94: 2449-2453
[Abstract][Full Text]
Petty, E. M., Killeen, A. A.
(1997). BRCA1 Mutation Testing: Controversies and Challenges. Clin. Chem.
43: 6-8
[Full Text]
Rohlfs, E. M., Learning, W. G., Friedman, K. J., Couch, F. J., Weber, B. L., Silverman, L. M.
(1997). Direct detection of mutations in the breast and ovarian cancer susceptibility gene BRCA1 by PCR-mediated site-directed mutagenesis. Clin. Chem.
43: 24-29
[Abstract][Full Text]
Smith, T M, Lee, M K, Szabo, C I, Jerome, N, McEuen, M, Taylor, M, Hood, L, King, M C
(1996). Complete genomic sequence and analysis of 117 kb of human DNA containing the gene BRCA1.. Genome Res.
6: 1029-1049
[Abstract]
Eeles, R.
(1996). Testing for the breast cancer predisposition gene, BRCA1. BMJ
313: 572-573
[Full Text]
Offit, K., Mathew, C. G., Solomon, E., Hodgson, S. V., Ithier, G., Girard, M., Stoppa-Lyonnet, D., Sher, C., Sharabani-Gargir, L., Shohat, M., Haber, D. A., Garber, J. E., Finkelstein, D. M., Langston, A. A., Malone, K. E., Ostrander, E. A.
(1996). Breast Cancer and BRCA1 Mutations. NEJM
334: 1197-1200
[Full Text]
Rosenblatt, D. S., Foulkes, W. D., Narod, S. A., Collins, F. S.
(1996). Genetic Screening for Breast Cancer. NEJM
334: 1200-1201
[Full Text]
Yates, J. R W
(1996). Recent Advances: Medical genetics. BMJ
312: 1021-1025
[Abstract][Full Text]
(1996). Breast Cancer Gene Mutations in Normal Population. Journal Watch Dermatology
1996: 16-16
[Full Text]
(1996). BREAST CANCER GENE MUTATIONS IN NORMAL POPULATION. JWatch General
1996: 2-2
[Full Text]
Langston, A. A., Malone, K. E., Thompson, J. D., Daling, J. R., Ostrander, E. A.
(1996). BRCA1 Mutations in a Population-Based Sample of Young Women with Breast Cancer. NEJM
334: 137-142
[Abstract][Full Text]
Collins, F. S.
(1996). BRCA1 -- Lots of Mutations, Lots of Dilemmas. NEJM
334: 186-188
[Full Text]
Previous
